Enhances the Availability of Information for Shire Marketed Medicines
BASINGSTOKE, England and PHILADELPHIA, October 25 /PRNewswire-FirstCall/ -- Bolstering its commitment to transparency in the reporting of clinical trial study results, Shire plc, the global specialty biopharmaceutical company, announced today the creation and availability of a new website that offers access to specific Shire-sponsored clinical trials. The new site provides scientific, non-promotional summaries of clinical trials in a consistent format, and is available at http://www.ShireStudyResults.org as well as through a link on the Shire corporate website at http://www.Shire.com and through the previously established industry sponsored site http://www.ClincalStudyResults.org.
“The creation of this new website helps us achieve our goal to ensure that patients and their families, as well as physicians and other healthcare providers, have access to accurate information related to Shire medicines,” said Eliseo Salinas MD, Chief Scientific Officer for Shire. “It’s important for patients and their caregivers to understand all aspects associated with the treatment options they may be considering, and this new tool, which offers clinical trial data dating back to 2002, provides a central source to this information for Shire-sponsored trials of our medicines.”
Shire Global Medical Affairs created this new website and Shire’s Research & Development Compliance team is responsible for its content and maintenance.
Shire Plc
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: http://www.shire.com
“Safe Harbor” Statement Under the Private Securities Litigation Reform Act of 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development (including the successful development of JUVISTA(R) (Human TGFbeta3)), manufacturing and commercialization (including the launch and establishment in the market of VYVANSE); the impact of competitive products, including, but not limited to the impact of those on Shire’s Attention Deficit and Hyperactivity Disorder (“ADHD”) franchise; patents, including but not limited to, legal challenges relating to Shire’s ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine) extended release (ADHD) and GA-GCB (Gene-Activated Glucocerebrosidane); Shire’s ability to secure new products for commercialization and/or development; Shire’s ability to benefit from its acquisition of New River Pharmaceuticals Inc.; and other risks and uncertainties detailed from time to time in Shire plc’s filings with the Securities and Exchange Commission, particularly Shire plc’s Annual Report on Form 10-K for the year ended December 31, 2006.
CONTACT: For further information please contact: Media, Jessica Mann (Rest
of the World), +44-(0)1256-894-280; Matthew Cabrey (North America),
+1-484-595-8248
